Stevens-Johnson syndrome and toxic epidermal necrolysis: A review of the literature

Annals of Allergy, Asthma and Immunology

Volumn 94, Issue 4, 2005, Pages 419-436

  Letko, Erik ^a   Papaliodis, Dean N ^a   Papaliodis, George N ^a   Daoud, Yassine J ^a   Ahmed, A Razzaque ^b,c   Foster, C Stephen ^a,d,e  

^a HARVARD MEDICAL SCHOOL   (United States)

^b NEW ENGLAND BAPTIST HOSPITAL   (United States)

^c HARVARD SCHOOL OF DENTAL MEDICINE   (United States)

^d Massachusetts Eye Research and Surgery Institute   (United States)

^e MASSACHUSETTS EYE AND EAR INFIRMARY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; CYCLOSPORIN; IMMUNOGLOBULIN; STEROID; THALIDOMIDE;

DATA BASE; DISABILITY; DISEASE CLASSIFICATION; HOSPITALIZATION; HUMAN; IMMUNITY; IMMUNOMODULATION; INFORMATION PROCESSING; LONG TERM CARE; MORBIDITY; PATHOLOGY; PATIENT CARE; PLASMAPHERESIS; PRIORITY JOURNAL; REVIEW; STATISTICAL SIGNIFICANCE; STEVENS JOHNSON SYNDROME; SURVIVAL RATE; TOXIC EPIDERMAL NECROLYSIS;

EID: 17444381936     PISSN: 10811206     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1081-1206(10)61112-X     Document Type: Review

References (180)

1. Stevens AM, Johnson FC. A new eruptive fever associated with stomatitis and ophthalmia: report of two cases in children. Am J Dis Child. 1922;24:526-533.
2. Thomas BA. The so-called Stevens-Johnson syndrome. BMJ. 1950;1:1393-1397.
3. Bastuji-Garin S, Rzany B, Stern RS, Shear NH, Naldi L, Roujeau JC. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol. 1993;129:92-96.
4. Roujeau JC. The spectrum of Stevens-Johnson syndrome and toxic epidermal necrolysis: a clinical classification. J Invest Dermatol 1994;102:28S-30S.
5. Assier H, Bastuji-Garin S, Revuz J, et al. Erythema multiforme with mucous membrane involvement and Stevens-Johnson syndrome are clinically different disorders with distinct causes. Arch Dermatol. 1995;131:539-543.
6. Ruiz-Maldonado R. Acute disseminated epidermal necrosis types 1, 2, and 3: study of sixty cases. J Am Acad Dermatol. 1985;13:623-635.
7. Lyell A. Requiem for toxic epidermal necrolysis. Br J Dermatol. 1990;122:837-846.
8. Roujeau JC. Stevens-Johnson syndrome and toxic epidermal necrolysis are severity variants of the same disease which differs from erythema multiforme. J Dermatol. 1997;24: 726-729.
9. Huff JC, Weston WL, Tonnesen MG, et al. Erythema multiforme: a critical review of characteristics, diagnostic criteria, and causes. J Am Acad Dermatol. 1983;8:763-775.
10. Inachi S, Mizutani H, Shimizu M. Epidermal apoptotic cell death in erythema multiforme and Stevens-Johnson syndrome: contribution of perforin-positive cell infiltration. Arch Dermatol. 1997;133:845-849.
11. Ting HC, Adam BA. Erythema multiforme: response to corticosteroid. Dermatologica. 1984;169:175-178.
12. Rzany B, Hering O, Mockenhaupt M, et al. Histopathological and epidemiological characteristics of patients with erythema exudativum multiforme major, Stevens-Johnson syndrome and toxic epidermal necrolysis. Br J Dermatol. 1996;135:6-11.
13. Porteous DM, Berger TG. Severe cutaneous reactions (Stevens-Johnson syndrome and toxic epidermal necrolysis) in human immunodeficiency virus infection. Arch Dermatol. 1991;127:740-741.
14. Chan HL, Stern RS, Arndt KA, et al. The incidence of erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis: a population-based study with particular reference to reactions caused by drugs among outpatients. Arch Dermatol. 1990;126:43-47.
15. Schopf E, Stuhmer A, Rzany B, et al. Toxic epidermal necrolysis and Stevens-Johnson syndrome: an epidemiologic study from West Germany. Arch Dermatol. 1991;127:839-842.
16. Strom BL, Carson JL, Halpern AC. A population-based study of Stevens-Johnson syndrome: incidence and antecedent drug exposure. Arch Dermatol. 1991;127:831-838.
17. Capella D, Laporte JR, Vidal X, et al. European network for the case-population surveillance of rare diseases (Euronet): a prospective feasibility study. Eur J Clin Pharmacol. 1998;53: 299-302.
18. Kaufman DW. Epidemiologic approaches to the study of toxic epidermal necrolysis. J Invest Dermatol. 1994;102:31S-33S.
19. Roujeau JC, Kelly JP, Naldi L, et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med. 1995;333:1600-1607.
20. Wolkenstein P, Charue D, Laurent P, et al. Metabolic predisposition to cutaneous adverse drug reactions: role in toxic epidermal necrolysis caused by sulfonamides and anticonvulsants. Arch Dermatol. 1995;131:544-551.
21. Rzany B, Mockenhaupt M, Baur S, et al. Epidemiology of erythema exudativum multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis in Germany (1990-1992): structure and results of a population-based registry. J Clin Epidemiol. 1996;49:769-773.
22. Patterson R, Miller M, Kaplan M, et al. Effectiveness of early therapy with corticosteroids in Stevens-Johnson syndrome: experience with 41 cases and a hypothesis regarding pathogenesis. Ann Allergy. 1994;73:27-34.
23. Power WJ, Ghoraishi M, Foster CS, et al. Analysis of the acute ophthalmic manifestations of the erythema multiforme/ Stevens-Johnson syndrome/toxic epidermal necrolysis spectrum. Ophthalmology. 1995;102:1669-1676.
24. Power WJ, Saidman SL, Zhang DS, et al. HLA typing in patients with ocular manifestation of Stevens-Johnson syndrome. Ophthalmology 1996;103:1406-1409.
25. Patterson R, Grammer L, Greenberger PA, et al. Stevens-Johnson syndrome (SJS): effectiveness of corticosteroids in management and recurrent SJS. Allergy Proc. 1992;13:89-95.
26. Mondino BJ, Brown SI, Biglan AW, et al. HLA antigens in Stevens-Johnson syndrome with ocular involvement. Arch Ophthalmol. 1982;100:1453-1454.
27. Foster CS, Fong LP, Azar D, et al. Episodic conjunctival inflammation after Stevens-Johnson syndrome. Ophthalmology. 1988;95:453-462.
28. Wuepper KD, Watson PA, Kazmierowski JA. Immune complexes in erythema multiforme and the Stevens-Johnson syndrome. J Invest Dermatol. 1980;64:368-371.
29. Patterson R, Dykewicz MS, Gonzalzles A, et al. Erythema multiforme and Stevens-Johnson syndrome: descriptive and therapeutic controversy. Chest. 1990;98:331-336.
30. Tsuroda N, Iwanaga T, Sairo T, et al. Rapidly progressive bronchiolitis obliterans associated with Stevens-Johnson syndrome. Chest. 1990;98:243-245.
31. Naldi L, Locati F, Marchesi L, et al. Incidence of toxic epidermal necrolysis in Italy. Arch Dermatol. 1990;126: 1103-1104.
32. Bottiger LE, Strandberg I, Westerholm B. Drug induced febrile mucocutaneous syndrome. Acta Med Scand. 1975;198: 229-233.
33. Marvin JA, Heimbach DM, Engraw LH, et al. Improved treatment of the Stevens-Johnson syndrome. Arch Surg. 1984;119:601-605.
34. McGee T, Munster A. Toxic epidermal necrolysis syndrome: mortality reduced with early referral to regional burn center. Plast Reconstr Surg. 1998;102:1018-1022.
35. Singer L, Brook U, Romen M, et al. Vitamin A in Stevens-Johnson syndrome. Ann Ophthalmol. 1989;21:209-210.
36. Chosidow O, Zohra EW, Devanlay M, et al. Hyperamylasemia in toxic epidermal necrolysis. Arch Dermatol. 1993;129: 792-793.
37. Pruitt BA. Burn treatment for the unburned. JAMA. 1987;257: 2207-2208.
38. Revuz J, Penso D, Roujeau JC, et al. Toxic epidermal necrolysis: clinical findings and prognosis factors in 87 patients. Arch Dermatol. 1987;123:1160-1165.
39. Egan CA, Grant WJ, Morris SE, et al. Plasmapheresis as an adjunct treatment in toxic epidermal necrolysis. J Am Acad Dermatol. 1999;40:458-461.
40. Stern RS, Chan HL. Usefulness of case report literature in determining drugs responsible for toxic epidermal necrolysis. J Am Acad Dermatol. 1989;21:317-322.
41. Paquet P, Nikkels A, Arrese JE, et al. Macrophages and tumor necrosis factor α in toxic epidermal necrolysis. Arch Dermatol. 1994;130:605-608.
42. Jones WG, Halebian P, Madden M, et al. Drug-induced toxic epidermal necrolysis in children. J Pediatr Surg. 1989;24:167-170.
43. Stein KM, Schlappner LA, Heaton CL, et al. Demonstration of basal cell immunofluorescence in drug-induced toxic epidermal necrolysis. Br J Dermatol. 1972;86:246-252.
44. Halebian PH, Corder VJ, Madden MR, et al. Improved burn center survival of patients with toxic epidermal necrolysis managed without corticosteroids. Ann Surg. 1986;204: 503-512.
45. McIvor RA, Zaidi J, Peters WJ, et al. Acute and chronic respiratory complications of toxic epidermal necrolysis. J Burn Care Rehabil. 1996;17:237-240.
46. Manzella J, Hall CB, Green JL, McMeekin TO. Toxic epidermal necrolysis in childhood: differentiation from staphylococcal scaled skin syndrome. Pediatrics. 1980;66:291-294.
47. Roujeau JC, Guillaume JC, Fabre JP, et al. Toxic epidermal necrolysis (Lyell syndrome): incidence and drug etiology in France, 1981-1985. Arch Dermatol. 1990;126:37-42.
48. Sakellariou G, Koukoudis P, Karpouzas J, et al. Plasma exchange (PE) treatment in drug-induced toxic epidermal necrolysis (TEN). Int J Artif Org. 1991;14:634-638.
49. Heng M, Allen S. Efficacy of cyclophosphamide in toxic epidermal necrolysis. J Am Acad Dermatol. 1991;25:778-786.
50. Guibal F, Bastuji-Garin S, Chosidow O, et al. Characteristics of toxic epidermal necrolysis in patients undergoing long-term glucocorticoid therapy. Arch Dermatol. 1995;131:669-672.
51. Bagot M, Charue D, Heslan M, et al. Impaired antigen presentation in toxic epidermal necrolysis. Arch Dermatol. 1993; 129:721-727.
52. Viard I, Wehrli P, Bullani R, et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science. 1998;282:490-493.
53. Villada G, Roujeau JC, Clerici T, et al. Immunopathology of toxic epidermal necrolysis: keratinocytes, HLA-DR expression, Langerhans cells, mononuclear cells: an immunopathologic study of five cases. Arch Dermatol. 1992;128:50-53.
54. Roujeau J, Dubertret L, Moritz S, et al. Involvement of macrophages in the pathology of toxic epidermal necrolysis. Br J Dermatol. 1985;113:425-430.
55. Westly ED, Wechsler HL. Toxic epidermal necrolysis: granulocytic leukopenia as a prognostic indicator. Arch Dermatol. 1984;120:721-726.
56. Birchall N, Langdon R, Cuono C, et al. Toxic epidermal necrolysis: an approach to management using cryopreserved allograft skin. J Am Acad Dermatol. 1987;16:368-372.
57. Paquet P, Pierard GE. Erythema multiforme and toxic epidermal necrolysis: a comparative study. Am J Dermatopathol. 1997;19:127-132.
58. Bjornberg A. Fifteen cases of toxic epidermal necrolysis (Lyell). Acta Dermatovener (Stockholm). 1973;53:149-152.
59. Adzik NS, Kim SH, Bondoc CC, et al. Management of toxic epidermal necrolysis in a pediatric burn center. Am J Dis Child. 1985;139:499-502.
60. Breathnach SM, McGibbon DH, Ive FA, et al. Carbamazepine ("Tegretol") and toxic epidermal necrolysis: report of three cases with histopathological observations. Clin Exp Dermatol. 1982;7:585-591.
61. Yetiv JZ, Bianchine JR, Owen JA. Etiologic factors of the Stevens-Johnson syndrome. South Med J. 1980;73:599-602.
62. Nomenclature for factors of the HLA system 1980. Eur J Immunol. 1981;11:350-352.
63. 125I C1q binding and skin immunofluorescence in erythema multiforme. J Invest Dermatol. 1980;74:375-378.
64. Guillaume JC, Roujeau JC, Revuz J, et al. The culprit drugs in 87 cases of toxic epidermal necrolysis (Lyell's syndrome). Arch Dermatol. 1987;123:1166-1170.
65. Goens J, Song M, Fondu P, et al. Haematological disturbance and immune mechanisms in toxic epidermal necrolysis. Br J Dermatol. 1986;114:255-259.
66. Orfanos CE, Schaumburg-Lever G, Lever WF. Dermal and epidermal types of erythema multiforme: a histopathologic study of 24 cases. Arch Dermatol. 1974;109:682-688.
67. Howland WW, Golitz LE, Weston WL, et al. Erythema multiforme: clinical, histopathologic, and immunologic study. J Am Acad Dermatol. 1984;10:438-446.
68. Nishida K, Yamanishi K, Yamada K, et al. Epithelial hyperproliferation and transglutaminase 1 gene expression in Stevens-Johnson syndrome conjunctiva. Am J Pathol. 1999; 154:331-336.
69. Elias PM, Fritsch P, Epstein EH. Staphylococcal scalded skin syndrome: clinical features, pathogenesis, and recent microbiological and biochemical developments. Arch Dermatol. 1977; 113:207-219.
70. Wolkenstein P, Latarjet J, Roujeau JC, et al. Randomized comparison of thalidomide versus placebo in toxic epidermal necrolysis. Lancet. 1998;352:1586-1589.
71. Kim PS, Goldfarb IW, Gaisford JC, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: a pathophysiologic review with recommendations for a treatment protocol. J Burn Care Rehabil. 1983;4:91-100.
72. Metry DW, Jung P, Levy ML. Use of intravenous immunoglobulin in children with Stevens-Johnson syndrome and toxic epidermal necrolysis. Pediatrics. 2003;112:1430-1436.
73. Morici MV, Galen WK, Shetty AK, et al. Intravenous immunoglobulin therapy for children with Stevens-Johnson syndrome. J Rheumatol. 2000;27:2494-2497.
74. Prins C, Vittorio C, Padilla RS, et al. Effect of high-dose intravenous immunoglobulin therapy in Stevens-Johnson syndrome: a retrospective, multicenter study. Dermatology. 2003;207:96-99.
75. Bachot N, Revuz J, Roujeau JC. Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective noncomparative study showing no benefit on mortality or progression. Arch Dermatol. 2003;139: 33-36.
76. Broadbent RV. Stevens-Johnson disease presenting with pneumothorax. Rocky Mt Med J. 1967;167:69-72.
77. Zweibaum B, Cohen H, Chandrasoma P. Gastrointestinal involvement complicating Stevens-Johnson syndrome. Gastroenterology. 1986;91:469-474.
78. Bloom H, Lowel TWI. Erythema multiforme with renal and myocardial injury. Proc R Soc Med. 1964;57:175.
79. Comaish JS, Kerr DNS. Erythema multiforme and nephritis. BMJ. 1961;2:84.
80. Onadeko BO. A review of Stevens-Johnson syndrome at the University College Hospital, Ibadan. West Afr Med J. 1970; 19:142.
81. Krumlovsky FA, Del Greco F, Herdson PB, et al. Renal disease associated with toxic epidermal necrolysis (Lyell's disease) (Lyell's disease) Am J Med. 1974;57:817-825.
82. Garcia DI, LeCleach L, Bocquet H, et al. Toxic epidermal necrolysis and Stevens-Johnson syndrome: does early withdrawal of causative drugs decrease the risk of death? Arch Dermatol. 2000;136:323-327.
83. Arnold HL Jr, Odom RB, James WD. Contact dermatitis; drug eruptions. In: Andrews' Diseases of the Skin: Clinical Dermatology. 8th ed. Philadelphia, PA: WB Saunders; 1990: 128-130.
84. Lyell A. Toxic epidermal necrolysis: an eruption resembling scalding of the skin. Br J Dermatol. 1956;68:355-361.
85. Lyell A. Toxic epidermal necrolysis (the scalded skin syndrome): a re-appraisal. Br J Dermatol. 1979;100:69-86.
86. Rasmussen JE. Toxic epidermal necrolysis: a review of 75 cases in children. Arch Dermatol. 1975;111:1135-1139.
87. Amon RB, Dimond RL. Toxic epidermal necrolysis: rapid differentiation between staphylococcal and drug-induced disease. Arch Dermatol. 1975;111:1433-1437.
88. Roujeau JC, Chosidow O, Saiag P, et al. Toxic epidermal necrolysis (Lyell syndrome). Am J Acad Dermatol. 1990;23: 1039-1058.
89. Hawk RJ, Storer JS, Daum RS. Toxic epidermal necrolysis in a 6-week year old infant. Pediatr Dermatol. 1985;2:197-200.
90. Pegram PS, Mountz JD, O'Bar PR. Ethambutol-induced toxic epidermal necrolysis. Arch Intern Med. 1972;141:1677-1678.
91. Schmidt D, Kluge W. Fatal toxic epidermal necrolysis following reexposure to phenytoin: a case report. Epilepsia. 1983; 24:440-443.
92. Dreyfuss DA, Gottlieb LJ, Wilkerson DK, et al. Survival after a second episode of toxic epidermal necrolysis. Ann Plast Surg. 1988;20:146-147.
93. De Groot R, Oranje AP, Vuzeski VD, et al. Toxic epidermal necrolysis probably due to Klebsiella pneumoniae sepsis. Dermatologica. 1984;169:88-90.
94. Rasmussen JE. Toxic epidermal necrolysis. Med Clin North Am. 1980;64:901-920.
95. Lyell A. A review of toxic epidermal necrolysis in Britain. Br J Dermatol. 1967;79:662-671.
96. Callaway JL, Tate WE. Toxic epidermal necrolysis caused by "gin and tonic" [letter]. Arch Dermatol. 1974;109:909.
97. Ramider GF, Davis JH, Ackerman AB. Fumigant-induced toxic epidermal necrolysis. Arch Dermatol. 1974;110: 103-104.
98. Thompson JA, Wansker BA. A case of contact dermatitis, erythema multiforme, and toxic epidermal necrolysis. J Am Acad Dermatol. 1981;5:666-669.
99. Foged EK. Toxic epidermal necrolysis from oil lamp fuel. Contact Dermatitis. 1984;11:135-136.
100. Phoon WH, Chan MOY, Rajan VS, et al. Stevens-Johnson syndrome associated with occupational exposure to trichlorethylene. Contact Dermatitis. 1984;10:270-276.
101. Valsecchi R, Cassina P, Cainelli T. Contact toxic epidermal necrolysis. Contact Dermatitis. 1987;16:277.
102. Billingham RE, Streilein JW. Toxic epidermal necrolysis and homologous disease in hamsters. Arch Dermatol. 1968;98: 528-539.
103. Streilein JW, Billingham RE. An analysis of graft-vs-host disease in Syrian hamsters, I: the epidermolytic syndrome: description and studies on its procurement. J Exp Med. 1970; 132:163-180.
104. Saiag P, Caumes E, Chosidow O, et al. Drug-induced toxic epidermal necrolysis (Lyell syndrome) in patients infected with the human immunodeficiency virus. J Am Acad Dermatol. 1992;26:567-574.
105. Villada G, Roujeau JC, Cordonnier C, et al. Toxic epidermal necrolysis after bone marrow transplantation: study of nine cases. J Am Acad Dermatol. 1990;23:870-875.
106. Roujeau JC, Huynh TN, Bracq C, et al. Genetic susceptibility to toxic epidermal necrolysis. Arch Dermatol. 1987;123: 1171-1173.
107. Dolan PA, Flowers FP, Araujo OE, et al. Toxic epidermal necrolysis. J Emerg Med. 1989;7:65-69.
108. Becker DS. Toxic epidermal necrolysis. Lancet. 1998;351: 1417-1419.
109. Prendiville JS, Hebert AA, Greenwald MJ, et al. Management of Stevens-Johnson syndrome and toxic epidermal necrolysis in children. J Pediatr. 1989;115:881-887.
110. Revuz J, Roujeau JC, Guillaume JC, et al. Treatment of toxic epidermal necrolysis. Arch Dermatol. 1987;123:1156-1158.
111. Cohen SG, Glick M, Schaeffer VH. Toxic epidermal necrolysis. Spec Care Dentist. 1989;9:6-9.
112. Heimbach DM, Engray LH, Marvin JA, et al. Toxic epidermal necrolysis: a step forward in treatment. JAMA. 1987;257: 2171-2175.
113. Snyder RA, Elias PM. Toxic epidermal necrolysis and staphylococcal scalded skin syndrome. Dermatol Clin. 1983;1: 235-248.
114. Avakian R, Flowers FP, Araujo OE, et al. Toxic epidermal necrolysis: a review. J Am Acad Dermatol. 1991;25:69-79.
115. Management of toxic epidermal necrolysis [editorial]. Lancet. 1984;2:1250-1252.
116. Meneux E, Wolkenstein P, Haddad B, et al. Vulvovaginal involvement in toxic epidermal necrolysis: a retrospective study of 40 cases. Obstet Gynecol. 1998;91:283-287.
117. Herman TE, Kushner DC, Cleveland RH. Esophageal stricture secondary to drug-induced toxic epidermal necrolysis. Pediatr Radiol. 1984;14:439-440.
118. Barrera JE, Meyers AD, Hartford EC. Hypopharyngeal stenosis and dysphagia complicating toxic epidermal necrolysis. Arch Otolaryngol Head Neck Surg. 1998;124:1375-1376.
119. Correira O, Delgado L, Ramos JP, et al. Cutaneous T-cell recruitment in toxic epidermal necrolysis: further evidence of CD8+ lymphocyte involvement. Arch Dermatol. 1993;129: 466-468.
120. Miyauchi H, Hosokawa H, Akaeda T, et al. T-cell subsets in drug-induced toxic epidermal necrolysis: possible pathogenic mechanism induced by CD8-positive T cells. Arch Dermatol. 1991;127:851-855.
121. Merot Y, Saurat JH. Clues to pathogenesis of toxic epidermal necrolysis. Int J Dermatol. 1985;24:165-168.
122. Merot Y, Gravallese E, Guillen FJ, et al. Lymphocyte subsets and Langerhans' cells in toxic epidermal necrolysis. Arch Dermatol. 1986;22:455-458.
123. Paul C, Wolkenstein CP, Adle H, et al. Apoptosis as a mechanism of keratinocyte death in toxic epidermal necrolysis. Br J Dermatol. 1996;134:710-714.
124. Posadas SJ, Torres MJ, Mayorga C, Juarez C, Blanca M. Gene expression levels of cytokine profile and cytotoxic markers in non-immediate reactions to drugs. Blood Cells Mol Dis. 2002; 29:179-189.
125. Sugimoto Y, Mizutani H, Sato T, et al. Toxic epidermal necrolysis with severe gastrointestinal mucosal cell death: a patient who excreted long tubes of dead intestinal epithelium. J Dermatol. 1998;25:533-538.
126. Lerner L, Qureshi A, Reddy B, et al. Nitric oxide synthase in toxic epidermal necrolysis and Stevens-Johnson syndrome. J Invest Derm. 2000;114:196-199.
127. Tagami H, Tatsuta K, Iwatski K, Yamada M. Delayed hypersensitivity in ampicillin-induced toxic epidermal necrolysis. Arch Dermatol. 1983;119:910-913.
128. Tatnall FM, Dodd HJ, Sarkany I, et al. Elevated serum amylase in a case of toxic epidermal necrolysis. Br J Dermatol. 1985; 113:629-630.
129. Roujeau JC, Koso M, Andre C, et al. Sjögren syndrome after drug-induced toxic epidermal necrolysis. Lancet. 1985;16:609-611.
130. Klein SM. Hepatitis, toxic epidermal necrolysis and pancreatitis in association with sulindac therapy. J Rheumatol. 1983; 10:512-513.
131. Zemtsov A. The cellular source of creatine kinase in patients with toxic epidermal necrolysis. Br J Dermatol. 1995;132: 487-488.
132. Caux F, Chosidow O, Philippen C, et al. Increased serum and blister fluid levels of creatinine kinase in patients with toxic epidermal necrolysis. Br J Dermatol. 1994;130:337-341.
133. O'Garra A. Interleukins and the immune system 1. Lancet. 1989;1:943-946.
134. Paquet P, Nusgens B, Pierard G, et al. Gelatinases in drug-induced toxic epidermal necrolysis. Eur J Clin Investig. 1998; 28:528-532.
135. Friedman PS, Strickland I, Pirmohamed M, et al. Investigation of mechanisms in toxic epidermal necrolysis induced by carbamazepine. Arch Dermatol. 1994;130:598-604.
136. Shear NH, Spielberg SP. Anticonvulsant hypersensitivity syndrome: in vitro assessment of risk. J Clin Invest. 1988;82:1826-1832.
137. Pirmohamed M, Graham A, Roberts P, et al. Carbamazepine-hypersensitivity: assessment of clinical and in vitro chemical cross-reactivity with phenytoin and oxcarbazepine. Br J Clin Pharmacol. 1991;32:741-749.
138. Park BK, Pirmohamed M, Kitteringham NR. Idiosyncratic drug reactions: a mechanistic evaluation of risk factors. Br J Clin Pharmacol. 1992;34:377-395.
139. Rieder MJ, Uetrecht J, Shear NH, et al. Diagnosis of sulfonamide hypersensitivity reactions by in vitro "rechalange" with hydroxylamine metabolites. Ann Intern Med. 1989;110: 286-289.
140. Larrey D, Berson A, Habersetzer F, et al. Genetic predisposition to drug hepatotoxicity: role in hepatitis caused by amineptin, a tricyclic antidepressant. Hepatology. 1989;10:168-173.
141. Cribier B, Piemont Y, Grosshans E, et al. Staphylococcal scalded skin syndrome in adults: a clinical review illustrated with a new case. J Am Acad Dermatol. 1994;319-324.
142. Demling RH, Ellerbe S, Lowe NJ. Burn unit management of toxic epidermal necrolysis. Arch Surg. 1978;113:758-759.
143. Tompkins RG, Burke JF. Burn therapy 1985: acute management. Intensive Care Med. 1986;12:289-295.
144. Goldstein SM, Wintroub BW, Elias PM, et al. Toxic epidermal necrolysis: unmuddying the waters. Arch Dermatol. 1987;123:1153-1156.
145. Halebian PH, Corder VJ, Herndon D, et al. A burn center experience with toxic epidermal necrolysis. J Burn Care Rehabil. 1983;4:176-183.
146. Pasulka PS, Wachtel TL. Nutritional considerations for the burned patient. Surg Clin North Am. 1987;67:109-131.
147. Gamelli RL. Nutritional problems of the acute and chronic burn patient: relevance to epidermolysis bullosa. Arch Dermatol. 1988;124:756-759.
148. Demling RH. Burns. N Engl J Med. 1985;313:1389-1398.
149. Loirat P, Rohan J, Baillet A, et al. Increased glomerular filtration rate in patients with major burns and its effect on the pharmacokinetics of tobramycin. N Engl J Med. 1978;299: 915-919.
150. MacFarlane AW, Curley R. Management of toxic epidermal necrolysis with a hydrogel dressing and fluidized-bead bed: report of three cases. Clin Exp Dermatol. 1987;12:354-356.
151. Prasad JK, Feller I, Thomson PD. Use of amnion for the treatment of Stevens-Johnson syndrome. J Trauma. 1986;26: 945-946.
152. Ruocco V, Vimonte D, Luongo C, et al. Hyperbaric oxygen treatment of toxic epidermal necrolysis. Cutis. 1986;38: 267-271.
153. Arstikaitis MJ. Ocular aftermath of Stevens-Johnson syn-drome. Arch Ophthalmol. 1973;90:376-379.
154. Romero-Rangel T, Stavrou P, Cotter J, et al. Gas permeable scleral contact lens therapy in ocular surface disease. Am J Ophthalmol. 2000;130:25-32.
155. Dohlman CH, Terada H. Keratoprosthesis in pemphigoid and Stevens-Johnson syndrome. Adv Exp Med Biol. 1998;438: 1021-1025.
156. Kamanabroo D, Schmitz-Landgraf W, Czarnetzki BM. Plasmapheresis in severe drug-induced toxic epidermal necrolysis. Arch Dermatol. 1985;121:1548-1549.
157. Arevalo JM, Lorente JA, Gonzalez-Herrada C, et al. Treatment of toxic epidermal necrolysis with cyclosporine A. J Trauma. 2000;48:473-478.
158. Furubacke A, Berlin G, Anderson C, et al. Lack of significant treatment effect of plasma exchange in the treatment of drug-induced toxic epidermal necrolysis. Intensive Care Med. 1999; 25:1307-1310.
159. Simons HM. Acute life-threatening dermatologic disorders. Med Clin North Am. 1981;65:227-243.
160. Moncada B, Quevedo ME, Lorincz AL. Abnormal T-cell response in toxic epidermal necrolysis. Arch Dermatol. 1994; 130:116-117.
161. Parsons JM. Management of toxic epidermal necrolysis. Cutis. 1985;36:305-307, 310-311.
162. Sheretz EF, Jegasothy BV, Lazarus GS. Phenytoin hypersensitivity reaction presenting with toxic epidermal necrolysis and severe hepatitis. J Am Acad Dermatol. 1985;12:178-181.
163. Rzany B, Schmitt H, Schopf E. Toxic epidermal necrolysis in patients receiving glucocorticosteroids. Acta Derm Venereol (Stockh). 1991;71:171-172.
164. Okano M, Kitano Y, Igarashi T. Toxic epidermal necrolysis due to rifampicin. J Am Acad Dermatol. 1987;17:303-304.
165. Gerard A, Schooneman F, Roche G, et al. Lyell's syndrome treatment by plasma exchange. Plasma Ther Transfus Technol. 1984;5:259-260.
166. Chaidemenos GC, Chrysomallis F, Sombolos K, et al. Plasmapheresis in toxic epidermal necrolysis. Int J Dermatol. 1997;36:218-221.
167. Klausner JD, Freedman VH, Kaplan G. Thalidomide as an anti-TNF-α inhibitor: implications for clinical use. Clin Immunol Immunopathol. 1996;81:219-223.
168. Moreira AL, Sampaio EP, Zmuidzinas A, et al. Thalidomide exerts its inhibitory action on tumor necrosis factor α by enhancing mRNA degradation. J Exp Med. 1993;177: 1675-1680.
169. Campione E, Marulli GC, Carrozzo AM, Chimenti MS, Costanzo A, Bianchi L. High-dose intravenous immunoglobulin for severe drug reactions: efficacy in toxic epidermal necrolysis. Acta Dermatol Venereol. 2003;83:430-432.
170. Trent JT, Kirsner RS, Romanelli P, Kerdel FA. Analysis of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis using SCORTEN: The University of Miami Experience. Arch Dermatol. 2003;139:39-43.
171. Prins C, Kerdel FA, Padilla RS, et al; TEN-IVIG Study Group. Toxic epidermal necrolysis-intravenous immunoglobulin. Arch Dermatol. 2003;139:26-32.
172. Tristani-Firouzi P, Petersen MJ, Saffle JR, Morris SE, Zone JJ. Treatment of toxic epidermal necrolysis with intravenous immunoglobulin in children. J Am Acad Dermatol. 2002;47: 548-552.
173. Stella M, Cassano P, Bollero D, Clemente A, Giorgio G. Toxic epidermal necrolysis treated with intravenous high-dose immunoglobulins: our experience. Dermatology. 2001;203: 45-49.
174. Renfro L, Grant-Kreis JM, Daman LA. Drug-induced toxic epidermal necrolysis treated with cyclosporine. Int J Dermatol. 1989;28:441-444.
175. Chan HL. Observations on drug-induced toxic epidermal necrolysis in Singapore. J Am Acad Dermatol. 1984;10: 973-978.
176. Ellman MH, Freitzin DF, Olson W. Toxic epidermal necrolysis associated with allopurinol administration. Arch Dermatol. 1975;111:986-990.
177. Roupe G, Ahlmen M, Fagerberg B, et al. Toxic epidermal necrolysis with extensive mucosal erosions of the gastrointestinal and respiratory tracts. Int Arch Allergy Appl Immunol. 1986;80:145-151.
178. Tagami H, Iwatsuki K. Elevated serum amylase in toxic epidermal necrolysis. Br J Dermatol. 1986;115:250-251.
179. Coetzer M, van der Merwe AE, Warren BL. Toxic epidermal necrolysis in a burn patient complicated by acute pancreatitis. Burns. 1998;24:181-183.
180. Moutsopoulos HM, Webber BL, Vlagopoulos TP, et al. Differences in the clinical manifestations of sicca syndrome in the presence and absence of rheumatoid arthritis. Am J Med. 1979;66:733-736.